DALLAS, July 20, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring pharmaceutical company Aradigm Corp. (OTCBB:ARDM). The report includes financial and comparative analyses, as well as pertinent industry information you need to know to make an educated investment decision.
The investment report on Aradigm Corp. (OTCBB:ARDM) should be of particular interest to other pharmaceutical companies: Novartis AG (NYSE:NVS), Biogen Idec Inc. (Nasdaq:BIIB), Genzyme Corp. (Nasdaq:GENZ) and Life Technologies Inc. (Nasdaq:LIFE).
It is available at: http://beaconequity.com/i/ARDM/
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Aradigm Corp. (ARMD) is an emerging pharmaceutical Company focused on the development and commercialization of specialty drug inhalation therapies for the treatment of pulmonoloical disorders in the United States. The Company addresses the treatment of cystic fibrosis bronchiectasis, pulmonary arterial hypertension, chronic obstructive pulmonary disease (COPD), inhalation anthrax infections, and smoking cessation in its pursuit of more effective drug-therapeutic means of treating these medical conditions.
Read and post on Twitter and top Stock Message Boards for these stocks and more, all in real-time: http://www.BoardCentral.com/
In the report, the analyst notes:
"The Company has several drug candidates in phase II clinical trials, which may increase the odds of successful FDA approval to better than the 50% approval rate expected from each successful phase II candidate.
"On July 16, the Company announced that Zogenix Inc. was granted approval for the needle-free drug delivery system, called Sumavel(TM) DosePro(TM), for the use with Zogenix's drug therapy to treat migraine headaches. ARDM's DosePro technology entitles the Company to a $4 million milestone payment and royalty payments from sales of its needle-free technology in the United States and other countries."
To read the entire report visit: http://beaconequity.com/i/ARDM/
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Equity, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.